The post Founders’ Journey: From Pharmacology to Patient Impact appeared first on Dignify Therapeutics.

Mr. Welch comes to Dignify with over two decades of diverse business experience as a successful entrepreneur and business executive from startup to acquisition. He has worked as a senior executive in clinical trials for pharmaceutical, biotechnology, and med-tech companies seeking to develop their assets into safe and effective treatment options. His experience includes multiple leadership roles in business development, branding, marketing, corporate communications, and strategic planning activities.

We are thrilled to welcome Jeff to our executive team,” said Anthony DiTonno, CEO of Dignify. His skills and experience align well with Dignify’s business priorities. As we enter a pivotal phase of growth, Jeff has a wide appreciation of the complexities associated with getting a drug or device to market. From fundraising and building a team of KOLs to navigating the regulatory landscape, he will be instrumental in executing our mission to bring Dignify’s treatments to patients.

About Dignify Therapeutics

Founded by a team of serial entrepreneurs who are internationally recognized scientists, Dignify Therapeutics’ mission is to provide practical and convenient treatments for bladder and bowel voiding dysfunctions, primarily using a repositioning strategy of drug discovery that the team has successfully implemented multiple times over the last 20 years in the fields of urology and gastroenterology.

The Company is funded by founders, venture capital firms (RA Capital Management and Eshelman Ventures), the North Carolina Biotechnology Center, the One NC Small Business Program, and the NIH SBIR/STTR program (with 18 awards and approximately $18 million in funding). Dignify Therapeutics is located in the First Flight Venture Center in Research Triangle Park, North Carolina. 

PRESS CONTACT

Dignify Therapeutics

Ed Burgard, PhD

2 Davis Drive

Research Triangle Park, NC  27709

Phone: 919-371-8138

Email:  eburgard@dignifytherapeutics.com

Website:  https://dignifytherapeutics.com

The post Dignify Therapeutics Announces Jeff Welch as Chief Operating Officer appeared first on Dignify Therapeutics.

The post Bolstering Bowel And Bladder Control With Dignify Therapeutics’ Karl Thor appeared first on Dignify Therapeutics.

During the conference, Dignify CEO Anthony DiTonno provided an update of the company’s progress and strategic direction. He emphasized Dignify Therapeutics’ commitment to developing innovative therapies for individuals affected by spinal cord injuries, diabetes, Parkinson’s disease, and other neurological conditions.

DTI-301 and DTI-117 are at the forefront of the company’s pipeline and are treatments for bladder and bowel dysfunction associated with neurological conditions and the aging process. Currently, many of these individuals require bladder catheterization for bladder emptying and an invasive, time-consuming manual bowel program for bowel evacuation. 

Dignify’s lead drug program, DTI-301, is a suppository that patients use as needed for bowel evacuation. DTI-301 induces defecation within 5-10 minutes, with minimal absorption and systemic exposure.  Dignify’s second drug program, DTI-117, is currently in development for on-demand emptying of both the bladder and bowel. DTI-117 directly stimulates smooth muscle contraction in the bladder and bowel, produces voiding in less than 10 minutes, and is rapidly eliminated from the body.

About Dignify Therapeutics

Dignify Therapeutics is a biotechnology company focused on developing therapies to restore voluntary bowel and bladder function in individuals with neurological conditions. The company’s mission is to improve the quality of life for individuals affected by neurological disorders, and the elderly.

For more information about Dignify Therapeutics and its clinical development programs, please visit www.dignifytherapeutics.com.

About the BIO CEO & Investor Conference

The BIO CEO & Investor Conference serves as a premier platform for biotech companies to engage with investors and industry leaders, fostering discussions on the latest advancements and investment opportunities in the biotechnology sector. 

PRESS CONTACT  

Dignify Therapeutics  

The post Dignify Therapeutics Highlights Clinical Development Plans at the BIO CEO & Investor Conference appeared first on Dignify Therapeutics.

RESEARCH TRIANGLE PARK, NC (October 22, 2024) – Dignify Therapeutics (Dignify), a leading developer of therapies for bladder and bowel dysfunction, has been selected as a participating company in the Praxis Spinal Cord Injury (SCI) Accelerate Program. SCI Accelerate is a commercialization program ‘geared towards healthcare companies with a product ready to launch into a market that will transform the lives of people living
with SCI’. Under the SCI Accelerate program, Dignify and Praxis will focus on the development of Dignify’s drug programs to treat bladder and bowel disorders in people with SCI.

Dr. Karl B. Thor, Chief Scientific Officer of Dignify, indicated; “The Praxis SCI Accelerate Program is critically important for Dignify to ensure that the clinical development program for our products provides the efficacy, safety, and convenience that are considered valuable and most important by SCI individuals for control of bowel
and bladder dysfunction. The selection of Dignify to join the Praxis SCI community confirms the unmet medical need for our therapeutics.”

Arushi Raina, Praxis Director of Commercialization, stated “The Praxis team was impressed by the Dignify team’s approach and excited by the possibility of a bowel and bladder treatment that could be used in an accessible way to transform daily living.”

About Dignify Therapeutics
Founded by a team of serial entrepreneurs who are internationally recognized scientists and clinicians, Dignify’s mission is to provide safe, effective, practical, and convenient, “on-demand” pharmaceutical agents to treat bladder and bowel voiding dysfunctions. The company has been funded by RA Capital Management, Eshelman
Ventures, the North Carolina Biotechnology Center, NIDDK, NINDS, NICHD, NIA, US Defense Department, and the One NC Small Business Program. Dignify is located at the First Flight Venture Center in Research Triangle Park, North Carolina.

About Praxis
Praxis is a Canadian-based not-for-profit organization that leads global collaboration in SCI research, innovation, and care. We accelerate the translation of discoveries and best practices into improved treatments for people with spinal cord injuries. Our work is driven by the priorities of people with SCI and led by our four teams — PLEX (people with lived experience), Cure, Care, and Commercialization.

PRESS CONTACT
Dignify Therapeutics
Anthony DiTonno, CEO
2 Davis Drive
Research Triangle Park, NC 27709
ditonno@dignifytherapeutics.com
dignifytherapeutics.com

The post Dignify Therapeutics Selected as a Praxis SCI Accelerate Company appeared first on Dignify Therapeutics.